Protalix BioTherapeutics Inc (AMEX:PLX)
$ 1.1 -0.15 (-12%) Market Cap: 80.65 Mil Enterprise Value: 73.37 Mil PE Ratio: 55.00 PB Ratio: 2.39 GF Score: 57/100

Q4 2020 Protalix Biotherapeutics Inc Earnings Call Transcript

Mar 30, 2021 / 12:30PM GMT
Release Date Price: $4.51 (-4.04%)
Operator

Good morning, ladies and gentlemen, and welcome to Protalix BioTherapeutics Fiscal Year 2020 Earnings Conference Call. As a reminder, this conference call is being recorded. I will now turn the conference over to our host, Mr. [David Holmes] of LifeSci Advisors, Investor Relations. You may begin your conference, sir. Please proceed.

Unidentified Participant

Thank you, operator. Welcome to Protalix BioTherapeutics' Fiscal Year 2020 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and Chief Executive Officer of Protalix; and Eyal Rubin, Chief Financial Officer. A press release announcing the results and the update was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference includes forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot